The complete official prescribing information should always be consulted for authoritative instructions. The summary below is based primarily on current U.S. LENVIMA labeling and is not a replacement for the official label.
Indications
Current U.S. labeling includes:
- Progressive radioactive-iodine-refractory differentiated thyroid cancer.
- Advanced renal cell carcinoma in specified combinations.
- First-line unresectable hepatocellular carcinoma.
- Certain advanced endometrial carcinoma in combination with pembrolizumab.
Dosage
Current U.S. dosing includes 24 mg once daily for DTC; 20 mg once daily with pembrolizumab for first-line RCC; 18 mg once daily with everolimus for previously treated RCC; weight-based 8 mg or 12 mg daily for HCC; and 20 mg daily with pembrolizumab for the specified EC indication.
Contraindications
The current U.S. label states that there are no listed contraindications. This does not mean the medicine is suitable for every patient. Warnings and precautions remain substantial.
Major warnings
The prescribing information addresses:
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal impairment
- Proteinuria
- Diarrhea
- Fistula formation and gastrointestinal perforation
- QT prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhage
- Thyroid dysfunction
- Impaired wound healing
- Osteonecrosis of the jaw
- Embryo-fetal toxicity
Complete authoritative document
Readers should consult the latest official prescribing information from the applicable regulatory authority rather than relying on a secondary summary.